Just days after raising more than $1B in its IPO, Quintiles announced Wednesday it signed a five-year clinical development agreement with Merck Serono. …
Merck Serono a division of Germany's Merck KGaA MRK DE announced detailed results from the randomized Phase III START trial of its investigational MUC1 antigenspecific cancer immunotherapy LBLP25 form…
Merck Serono announced that based on its recent analysis of the human growth hormones HGH market Frost & Sullivan recognises Merck Serono with the 2013 Europe Product Differentiation Excellence Aw…
Quintiles inks five-year clinical development partnership with Merck Serono…
